What question did this study set out to answer?

To characterize the late-onset complications of CAR-T therapy, particularly IEC-HS, and establish effective management strategies.

December 8, 2025BloodOpen Access

Unveiling the “second wave”: Viral-triggered biphasic CAR-T expansion drives late-onset IEC-HS: Characterization and successful management

View Full Paper

Ask AI

Bookmark

Authors

Retrospective analysis found CAR-T expansion triggers late-onset IEC-HS in patients, indicating effective management strategies are needed.

To characterize the late-onset complications of CAR-T therapy, particularly IEC-HS, and establish effective management strategies.
Retrospective cohort study of 79 patients receiving CAR-T cell therapy.
Identified cases of late-onset IEC-HS using established HLH diagnostic criteria.
Employed high-dimensional spectral flow cytometry to analyze CAR-T cell profiles.
14 patients (17.7%) developed late-onset IEC-HS with a median onset of 32 days post-infusion.
Pathogen-mediated CAR-T cell reactivation was the primary trigger, mainly due to viral infections such as CMV.
Managing hyper-inflammation effectively in over 90% of cases with low-dose etoposide tailored to proliferation kinetics.

Su et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Retrospective analysis found CAR-T expansion triggers late-onset IEC-HS in patients, indicating effective management strategies are needed.